Strasbourg, France, February 4, 2026, 5:45 p.m. CET – Transgene (Euronext Paris: TNG) a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, ...
Strasbourg, France, January 23, 2026, 8:00 a.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announced ...
'Our new but simple method is far more effective and can now be applied to a much wider range of plant species than our original approach' Genetically modified organisms, also known as GMOs, have been ...
Transgene’s Two Innovative Platforms Progressing Well - Financial Visibility Extended Until End 2023
STRASBOURG, France--(BUSINESS WIRE)--Regulatory News: Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, ...
The company is advancing TG4050 in head and neck cancer and possibly to other tumor types based on encouraging Phase I data.
Genetic engineering in non-human primates has been challenged by the limitations of virus-based gene delivery methods. Recently, researchers in Japan successfully used a nonviral system to introduce a ...
*** About Transgene Transgene (Euronext: TNG) is a biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer. Transgene’s programs utilize viral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results